Opening Recap
Market Pulse: Tech dragged US stocks lower Friday while Asia limped mixed, with India’s Nifty eyeing a breakout.
Key Movers: Broadcom’s earnings beat couldn’t stop a premarket slide, Milestone and Innoviva just secured FDA green lights, and cannabis policy shifts are stirring volatility.
Macro & Politics: Trump’s rescheduling of marijuana to Schedule III promises tax relief but opens fresh legal hurdles, and the Warner Bros merger fight is Hollywood’s next boardroom brawl.
What’s Next: Expect another wave of tech reports, keep scanners on healthcare stocks chasing FDA buzz, and monitor Beltway moves on cannabis for new trade catalysts.
Unfiltered Market Commentary
Everyone’s underestimating how quickly momentum chasers can steamroll a headline beat. Broadcom stunned Wall Street with a Q4 beat (Crypto Briefing) only to watch shares dip premarket—classic sell-the-news madness. Meanwhile, Milestone got FDA approval for CARDAMYST™ and Innoviva’s Nuzolvence green light didn’t make a ripple beyond pharma desks. That whipsaw is a reminder: future growth signals matter more than past jumps, and traders are ruthless. If you’re digging for outliers, don’t sleep on those nasal sprays.
The disconnect between healthcare wins and tech tumbles is eye-popping. On one hand, ASX 200 stocks are ripping on approval cheers (Motley Fool Australia), while on the other, the Warner Bros merger fight headlines (ABC News) overshadow real deal premiums. It’s as if markets treat science catalysts and boardroom brawls as separate acts, when both hinge on catalysts and conviction shifts. That’s the thesis: whether it’s approval milestones or billionaire showdowns, volatility follows decisive moments. Stay alert for these cross-asset flashpoints.
Action time: scan biotech tickers for volume spikes after FDA nods—those monster candles don’t lie. Keep an eye on cannabis plays as Schedule III rescheduling drums up tax talk and courtroom chaos (CBS News). And don’t ignore media M&A noise—it often sparks ripples in debt and equity pockets. Load your scanner with these names and let the market’s raw moves guide your strikes.
📈 Breaking Financial News
This ASX 200 stock is charging higher on FDA approval news
This stock is avoiding the market weakness on Monday. Let's find out why.
The post This ASX 200 stock is charging higher on FDA approval news appeared first on The Motley Fool Australia.
Milestone Pharmaceuticals receives FDA approval of CARDAMYST
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a presc…
Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Broadcom shares drop premarket despite Q4 earnings beat
Investor concerns over guidance updates may overshadow strong earnings, highlighting the market's sensitivity to future growth signals.
The post Broadcom shares drop premarket despite Q4 earnings beat appeared first on Crypto Briefing.
Oil Jumps 8.5% on Middle East Crisis
Experts predict $100+ oil if conflict spreads. Don't chase volatile oil stocks. See Marc's safer alternative here
🔍 Market Analysis & Insights
A break above 26,300 key for next Nifty rally: Analysts
Nifty has stabilized near recent highs, consolidating after a rebound from the 25,700 zone. The index faces resistance at 26,050–26,300, with a decisive move above this level potentially leading to a rally towards 26,350–26,500. Immediate support is seen at 2…
Trump reschedules marijuana to Schedule III, promising tax relief but raising new legal and industry concerns
Trump's decision to move marijuana to Schedule III could ease taxes and expand medical access, but industry leaders warn it may also trigger stricter federal oversight and new legal risks.
Crypto market’s weekly winners and losers – M, ZEC, STORY, JUP
This week, high-caps fell below key levels. Here’s a look at how some of your favorite coins fared.
S&P Inclusion Adds to the Excitement Around Comfort Systems (FIX) stock
Comfort Systems (NYSE:FIX) is one of the 10 Data Center Cooling Companies to Invest In . On December 5, Comfort Systems was selected to become a part of the …
Wearable Health Devices Market Size 2026 | Technology & Market Growth 2033
Download Sample Get Special Discount Wearable Health Devices Market Size, Strategic Outlook & Forecast 2026-2033Market size (2024): USD 40.5 billionForecast (2033): 125.
The Liquidity Engine Powering Crypto's Comeback
Institutional capital is flooding in while most investors remain completely unaware – creating what could be the buying opportunity of a lifetime. Exposed: Crypto's liquidity backbone set for massive gains – get all details for just $3!
💰 Investment Opportunities
Jim Cramer Says “I Think That You Buy Shake Shack at $79 a Share”
Shake Shack Inc. (NYSE:SHAK) is one of the stocks on Jim Cramer’s radar recently. A caller asked about the stock, and here’s what Mad Money’s host had to say…
Warner Bros battle draws in billionaires, celebrities and Trump's son-in-law
The dramatic escalation in the fight for Warner Bros is one of the biggest in recent corporate memory, drawing an unlikely cast of celebrities and business figures including Jared Kushner.
Stock market today: Dow, S&P 500, Nasdaq sink amid tech exodus on Wall Street
Wall Street is diversifying out of tech stocks, with Broadcom the latest AI name to disappoint after earnings.
What 3 announcements sent Lululemon shares soaring today
Lululemon Athletica saw its stock price surge approximately 10% in premarket trading Friday morning, climbing to $207.01 from its previous close of $187.62. The dramatic jump came after the athletic apparel retailer delivered a trio of major announcements tha…
Earnings live: Broadcom stock falls despite upbeat outlook, Lululemon pops, Costco dips
The third quarter earnings season has been mostly positive, with most of the reports in the rearview mirror.
Alert: The DeFi Token Set to Explode as Markets Recover
This isn't speculation – this platform's role is so essential to crypto's financial system that its current price defies all logic. Just Released: The DeFi token set for massive gains as markets heat up – only $3!